1. What ANORO ELLIPTA is and what it is used for
What ANORO ELLIPTA is
ANORO ELLIPTA contains two active substances umeclidinium bromide and vilanterol. These belong to a group of medicines called bronchodilators.
What ANORO ELLIPTA is used for
ANORO ELLIPTA is used to treat chronic obstructive pulmonary disease ( COPD ) in adults. COPD is a chronic disease that is characterized by difficulty breathing and that slowly worsens.
In COPD, the muscles around the airways contract. This medicine prevents the muscles in the lungs from contracting so that the air can pass more easily. When used regularly, it can help control your breathing difficulties and reduce the effects of COPD on your daily life.
ANORO ELLIPTA should not be used to treat a sudden attack of shortness of breath or wheezing.
If you get such an attack, you must use a fast-acting inhaler (eg salbutamol ). Contact your doctor if you do not have a fast-acting inhaler.
What you need to know before using ANORO ELLIPTA
Do not use ANORO ELLIPTA:
- if you are allergic to umeclidinium, vilanterol, or any of the other ingredients of this medicine (listed in section 6).
If you think this applies to you, do not use this medicine until you have talked to your doctor.
Warnings and cautions
Talk to your doctor before using this medicine:
- if you have asthma (do not use ANORO ELLIPTA to treat asthma )
- if you have heart problems or high blood pressure
- if you have an eye disease called narrow-angle glaucoma
- if you have an enlarged prostate, difficulty urinating, or an obstruction in the bladder
- if you suffer from epilepsy
- if you have thyroid problems
- if you have diabetes
- if you have severe liver problems.
Talk to your doctor if you think any of these may apply to you.
Acute breathing difficulties
If you get a chest tightness, cough, wheeze, or shortness of breath immediately after using the ANORO ELLIPTA inhaler:
Stop using this medicine and seek medical attention immediately. It can be a serious condition called paradoxical bronchospasm
Eye problems during treatment with ANORO ELLIPTA
If you experience pain or discomfort in the eyes, temporarily blurred vision, see light rings or colored dots in combination with red eyes during treatment with ANORO ELLIPTA.
Stop using this medicine and seek medical attention immediately. This may be a sign of acute narrow-angle glaucoma.
Children and young people
Do not give this medicine to children and adolescents under 18 years of age.
Other medicines and ANORO ELLIPTA
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. If you are not sure what your medicine contains, talk to your doctor or pharmacist.
Some medicines may affect the way this medicine works, or increase the risk of side effects. These are:
- so-called beta-blockers (such as propanol) used to treat high blood pressure and other heart problems
- ketoconazole and itraconazole used to treat fungal infections
- clarithromycin and telithromycin used to treat bacterial infections
- ritonavir used to treat HIV – infection
- drugs that lower the amount of potassium in the blood e.g. diuretics ( diuretic tablets) or medicines used to treat asthma (eg methylxanthines or steroids ).
- other long-acting drugs that are similar to this drug and are used for breathing problems, e.g. tiotropium and indacaterol. Do not use ANORO ELLIPTA if you are already taking these medicines.
Tell your doctor or pharmacist if you are taking any of these medicines.
Pregnancy and breastfeeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Do not use this medicine during pregnancy unless your doctor tells you to.
It is not known whether the ingredients in ANORO ELLIPTA can pass into breast milk. If you are breast-feeding, you must consult your doctor before using ANORO ELLIPTA. Do not use this medicine while breast-feeding unless your doctor advises you to do so.
Driving and using machines
ANORO ELLIPTA is likely to have no effect on your ability to drive or use machines.
ANORO ELLIPTA contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
How to use ANORO ELLIPTA
Always use this medicine exactly as your doctor has told you. Ask your doctor or pharmacist if you are unsure.
The recommended dose is one inhalation (inhalation) at the same time each day. You only need to inhale once a day as the effect of this medicine lasts for 24 hours.
Do not use more medicines than your doctor tells you to.
Use ANORO ELLIPTA regularly
It is very important that you use ANORO ELLIPTA every day according to your doctor’s instructions. That way, you can be helped to be symptom-free all day and night.
ANORO ELLIPTA should not be taken to treat a sudden attack of shortness of breath or wheezing. If you get such an attack, you must use a fast-acting inhaler (eg salbutamol ).
How to use the inhaler
For complete information, see “ Step-by-Step Instructions for Use ” after section 6 of this leaflet.
ANORO ELLIPTA is for inhalation only . To use ANORO ELLIPTA, inhale the medicine into your lungs through your mouth with the ELLIPTA inhaler.
If your symptoms do not get better
If your COPD symptoms (shortness of breath, wheezing, coughing) do not improve or get worse, or if you use your fast-acting inhaler more often than before:
Contact your doctor as soon as possible.
If you use more ANORO ELLIPTA than you should
If you happen to take too much of this medicine, contact your doctor or pharmacist immediately for advice, as you may need medical attention. If possible, show the inhaler, package, or package leaflet. Your heart may beat faster than normal, you may feel shaky, have visual disturbances, have a dry mouth, or a headache.
If you forget to use ANORO ELLIPTA
Do not inhale any extra dose to make up for a forgotten dose. Only inhale the next dose at the usual time.
If you experience wheezing or shortness of breath, use your fast-acting inhaler (eg salbutamol ), then seek medical attention.
If you stop using ANORO ELLIPTA
Use this medicine for as long as your doctor prescribes it. This medicine will only work as long as you use it. Do not stop using it unless your doctor advises you to do so, not even if you feel better, as your symptoms may worsen.
If you have any further questions on the use of this product, ask your doctor, pharmacist, or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you get any of the following symptoms while taking ANORO ELLIPTA, stop using this medicine and tell your doctor immediately :
Uncommon side effects ( may affect up to 1 in 100 people):
- skin rash ( hives ) or redness
Rare side effects are (may affect up to 1 in 1000 people)
- swelling, sometimes in the face or mouth ( angioedema )
- severe wheezing/wheezing, coughing, or difficulty breathing
- a sudden feeling of weakness or dizziness (which may lead to collapse or unconsciousness)
Acute breathing difficulties
Acute breathing difficulties after using ANORO ELLIPTA are rare. If you get a chest tightness, cough, wheeze, or shortness of breath immediately after using this medicine:
Stop using ANORO ELLIPTA and seek medical attention immediately, as you may have a serious condition called paradoxical bronchospasm.
Common side effects are
These can occur in up to 1 in 10 people:
- painful and frequent urination (may be a sign of urinary tract infection)
- a combination of sore throat and runny nose
- sore throat
- the feeling of pressure or pain in the cheeks or forehead (may be a sign of sinusitis, so-called sinusitis )
- pain and irritation in the back of the mouth and throat
- dry mouth
- upper respiratory tract infection.
Uncommon side effects are
These can occur in up to 1 in 100 people:
- irregular heartbeats
- faster heartbeat
- palpitations ( palpitation )
- changed taste experience
Rare side effects are
These can occur in up to 1 in 1,000 people:
- increase in the measured pressure in the eye
- impaired vision or pain in your eyes due to high pressure (possible signs of glaucoma )
- difficulty and pain when urinating – this may be a sign of bladder obstruction or urinary retention.
Has been reported
The frequency can not be calculated from the available data:
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Medical Products Agency, www.lakemedelsverket.se. By reporting side effects, you can help increase drug safety information.
5. How to store ANORO ELLIPTA
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, tray, and inhaler after “EXP”. The expiration date is the last day of the specified month.
Store the inhaler in the sealed trough and remove it immediately before using it for the first time. Moisture sensitive. Once the foil package has been opened, the inhaler can be used for up to 6 weeks, starting from the day the foil package has been opened. Write the date on which the inhaler is to be disposed of in the space provided on the label. The date should be written as soon as the inhaler has been removed from the foil package.
Do not store above 30 ° C.
If the inhaler is stored in a refrigerator, allow it to reach room temperature for at least one hour before use.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
6. Contents of the packaging and other information
What ANORO ELLIPTA contains
The active substances are umeclidinium bromide and vilanterol.
Each inhalation delivers a dose (the dose leaving the mouthpiece) of 55 micrograms umeclidinium (equivalent to 65 micrograms umeclidinium bromide) and 22 micrograms vilanterol (as triphenate).
The other ingredients are lactose monohydrate (see section 2 under ANORO ELLIPTA contains lactose ) and magnesium stearate.
What ANORO ELLIPTA looks like and contents of the pack
ANORO ELLIPTA is an inhalation powder, divided dose .
The Ellipta inhaler consists of a light gray plastic body with a red protective cap over the mouthpiece and a dose counter. It is packed in a foil-laminated tray with a peel-off foil lid. The tray contains a bag of desiccant to reduce the moisture in the package.
The active substances consist of a white powder in separate blisters inside the inhaler. Each inhaler contains either 7 or 30 doses. Multipacks of 90 doses (3 inhalers x 30) are also available. Not all pack sizes may be marketed.
Marketing Authorisation Holder
GlaxoSmithKline (Ireland) Limited
Citywest Business Campus
Glaxo Operations UK Limited (operating under the name Glaxo Wellcome Operations)
Glaxo Operations UK Ltd. (operating under the name Glaxo Wellcome Operations)
County Durham DL12 8DT
Glaxo Wellcome Production
Industrial Zone No.2,
23 Rue Lavoisier,
|Belgium / Belgique / BelgienGlaxoSmithKline Pharmaceuticals sa / nvTel: + 32 (0) 10 85 52 00||Luxembourg / LuxemburgGlaxoSmithKline Pharmaceuticals sa / nvBelgium / BelgiumTel: + 32 (0) 10 85 52 00|
|BulgariaThe GlaxoSmithKlein ЕООДTel .: + 359 2 953 10 34||HungaryGlaxoSmithKline Kft.Tel .: + 36 1 225 5300|
|Czech RepublicGlaxoSmithKline, sroTel: + 420 222 001 email@example.com||MaltaGlaxoSmithKline (Malta) LimitedTel: + 356 21 238131|
|DenmarkGlaxoSmithKline Pharma A / STel: + 45 36 35 91 firstname.lastname@example.org||The NetherlandsGlaxoSmithKline BVTel: + 31 (0) 30 email@example.com|
|GermanyGlaxoSmithKline GmbH & Co. KGTel .: + 49 (0) 89 36044 firstname.lastname@example.org||NorwayGlaxoSmithKline ASTel: + 47 22 70 20 00|
|EestiGlaxoSmithKline Eesti OÜTel: + 372 6676 email@example.com||AustriaGlaxoSmithKline Pharma GmbHTel: + 43 (0) 1 97075 firstname.lastname@example.org|
|GreeceGlaxoSmithKline AEBE:Ηλ: + 30 210 68 82 100||PolandGSK Services Sp. z ooTel .: + 48 (0) 22 576 9000|
|SpainGlaxoSmithKline, SATel: + 34 902 202 email@example.com||PortugalGlaxoSmithKline – Pharmaceutical Products, Lda.Tel: + 351 21 412 95 00FI.PT@gsk.com|
|FranceGlaxoSmithKline LaboratoryTel: + 33 (0) 1 39 17 84 firstname.lastname@example.org||RomaniaGlaxoSmithKline (GSK) SRL Tel: + 4021 3028 208|
|CroatiaGlaxoSmithKline dooTel: + 385 1 6051999||SloveniaGlaxoSmithKline dooTel: + 386 (0) 1 280 25 email@example.com|
|IrelandGlaxoSmithKline (Ireland) LimitedTel: + 353 (0) 1 4955000||Slovak RepublicGlaxoSmithKline Slovakia sroTel: + 421 (0) 2 48 26 11 firstname.lastname@example.org|
|IcelandVistor hf.Phone: + 354 535 7000||Finland / FinlandGlaxoSmithKline OyPuh / Tel: + 358 (0) 10 30 30 30Finland.email@example.com|
|ItalyGlaxoSmithKline SpATel: + 39 (0) 45 9218 111|
|ΚύπροςGlaxoSmithKline (Cyprus) Ltd:Ηλ: + 357 22 39 70 firstname.lastname@example.org||United KingdomGlaxoSmithKline UKTel: + 44 (0) 800 email@example.com|
|LatviaGlaxoSmithKline Latvia SIATel: + 371 firstname.lastname@example.org|
|LithuaniaGlaxoSmithKline Lithuania UABTel: + 370 5 264 90 email@example.com|